2016 / 04

Next Paper
DOI: 10.24075/brsmu.2016-04-02

ORIGINAL RESEARCH

Fluorescence imaging of actin cytoskeleton changes in cancer cells upon chemotherapy

Klementieva NV1, Furman OE1,2, Mishin AS1,3, Lukyanov KA1,3, Zagaynova EV1
About authors

1 Research Institute of Biomedical Technologies,
Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia

2 Lobachevsky State University of Nizhny Novgorod – National Research University, Nizhny Novgorod, Russia

3 Laboratory of Biophotonics, Department of Genetics and Postgenomic Technologies,
M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia

Correspondence should be addressed: Natalia Klementieva
pl. Minina i Pozharskogo, d. 10/1, Nizhny Novgorod, Russia, 603005; moc.liamg@aveitnemelkvn

About paper

Funding: this work was supported by the Russian Science Foundation (project no. 14-25-00129).

Acknowledgements: authors thank the IBCH Core Facility for the equipment.

Received: 2016-08-15 Accepted: 2016-08-25 Published online: 2017-01-05
|
  1. Bezanilla M, Gladfelter AS, Kovar DR, Wei-Lih L. Cytoskeletal dynamics: A view from the membrane. J Cell Biol. 2015; 209 (3): 329–37.
  2. Shutova MS, Alexandrova AY. [Comparative research of normal and transformed fibroblast spreading. The role of microfilament polymerization and actin-myosin contractility]. Tsitologiya. 2010; 52 (1): 41–51. Russian.
  3. Stevenson RP, Veltman D, Machesky LM. Actin-bundling proteins in cancer progression at a glance. J Cell Sci. 2012; 125 (Pt 5): 1073–9.
  4. Groth-Pedersen L, Aits S, Corcelle-Termeau E, Petersen NHT, Nylandsted J, Jäättelä M. Identification of Cytoskeleton-Associated Proteins Essential for Lysosomal Stability and Survival of Human Cancer Cells. PLoS One. 2012; 7 (10): e45381.
  5. Chen QY, Xu LQ, Jiao DM, Yao QH, Wang YY, Hu HZ, et. al. Silencing of Rac1 modifies lung cancer cell migration, invasion and actin cytoskeleton rearrangements and enhances chemosensitivity to antitumor drugs. Int J Mol Med. 2011 Nov; 28 (5): 769–76.
  6. Bonello TT, Stehn JR, Gunning PW. New approaches to targeting the actin cytoskeleton for chemotherapy. Future Med Chem. 2009 Oct; 1 (7): 1311–31.
  7. Brayford S, Schevzov G, Vos J, Gunning P. The Role of the Actin Cytoskeleton in Cancer and Its Potential Use as a Therapeutic Target. В книге: Schatten H, editor. The Cytoskeleton in Health and Disease. Luxemburg: Springer Science + Business Media; 2015. p.  373–91.
  8. Gross SR. Actin binding proteins: their ups and downs in metastatic life. Cell Adh Migr. 2013 Mar–Apr; 7 (2): 199–213.
  9. Nürnberg A, Kitzing T, Grosse R. Nucleating actin for invasion. Nat Rev Cancer. 2011; 11 (3): 177–87.
  10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16; 65 (1–2): 55–63.
  11. Lukinavičius G, Reymond L, D’Este E, Masharina A, Göttfert F, Ta H, et al. Fluorogenic probes for live-cell imaging of the cytoskeleton. Nat Methods. 2014 Jul; 11 (7): 731–3.
  12. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012 Jun; 9 (7): 676–82.
  13. Klementieva NV, Bozhanova NG, Mishina NM, Zagaynova EV, Lukyanov KA, Mishin AS. Common fluorescent proteins for single-molecule localization microscopy. Proc SPIE. 2015 Jul; 9536 (953609): [6 p.] DOI: 10.1117/12.2184924.
  14. Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD, Li SD. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res. 2013 Aug 1; 73 (15): 4862–71.
  15. Rosenblum MD, Shivers RR. “Rings” of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 2000; 125 (1): 121–31.
  16. Bottone MG, Soldani C, Tognon G, Gorrini C, Lazzè MC, Brison O, et al. Multiple effects of paclitaxel are modulated by a high c-myc amplification level. Exp Cell Res. 2003 Oct 15; 290 (1): 49–59.
  17. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 1998 Aug 15; 58 (16): 3620–6.
  18. Takito J, Otsuka H, Yanagisawa N, Arai H, Shiga M, Inoue M, et al. Regulation of Osteoclast Multinucleation by the Actin Cytoskeleton Signaling Network. J Cell Physiol. 2015 Feb; 230 (2): 395–405.
  19. Dutartre H, Davoust J, Gorvel JP, Chavrier P. Cytokinesis arrest and redistribution of actin-cytoskeleton regulatory components in cells expressing the Rho GTPase CDC42Hs. J Cell Sci. 1996 Feb; 109 (Pt 2): 367–77.
  20. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 Oct 5; 740: 364–78.
  21. Shen DW, Liang XJ, Gawinowicz MA, Gottesman MM. Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol. 2004 Oct; 66 (4): 789–93.
  22. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012 Jul; 64 (3): 706–21.
  23. Sharma S, Santiskulvong C, Bentolila LA, Rao J, Dorigo O, Gimzewski JK. Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine. 2012 Jul; 8 (5): 757–66.